Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Pharmacologically pertinent period of effect (PPPE).

Suissa M, LeLorier J.

Pharmacoepidemiol Drug Saf. 2019 Jan 9. doi: 10.1002/pds.4714. [Epub ahead of print]

PMID:
30628139
2.

Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Mitchell D, Guertin JR, LeLorier J.

Mol Diagn Ther. 2018 Dec;22(6):641-652. doi: 10.1007/s40291-018-0356-6.

PMID:
30218425
3.

Long-term Mortality After Acute Kidney Injury in the Pediatric ICU.

Hessey E, Morissette G, Lacroix J, Perreault S, Samuel S, Dorais M, Jouvet P, Lafrance JP, LeLorier J, Phan V, Palijan A, Pizzi M, Roy L, Zappitelli M.

Hosp Pediatr. 2018 May;8(5):260-268. doi: 10.1542/hpeds.2017-0215.

4.

Healthcare Utilization after Acute Kidney Injury in the Pediatric Intensive Care Unit.

Hessey E, Morissette G, Lacroix J, Perreault S, Samuel S, Dorais M, Phan V, Jouvet P, Lafrance JP, LeLorier J, Palijan A, Pizzi M, Roy L, Zappitelli M.

Clin J Am Soc Nephrol. 2018 May 7;13(5):685-692. doi: 10.2215/CJN.09350817. Epub 2018 Apr 20.

5.

A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.

Mitchell D, Guertin JR, Dubois A, Dubé MP, Tardif JC, Iliza AC, Fanton-Aita F, Matteau A, LeLorier J.

Mol Diagn Ther. 2018 Apr;22(2):241-254. doi: 10.1007/s40291-018-0323-2.

PMID:
29651791
6.

Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.

Perreault S, Shahabi P, Côté R, Dumas S, Rouleau-Mailloux É, Feroz Zada Y, Provost S, Mongrain I, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP.

Clin Cardiol. 2018 May;41(5):576-585. doi: 10.1002/clc.22948. Epub 2018 May 15.

7.

The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients.

Lepeytre F, Cardinal H, Fradette L, Verhave J, Dorais M, LeLorier J, Pichette V, Madore F.

Clin Kidney J. 2017 Jun;10(3):375-380. doi: 10.1093/ckj/sfw144. Epub 2017 Feb 18.

8.

Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario.

Perrault L, Dahan S, Iliza AC, LeLorier J, Zhanel GG.

Can J Infect Dis Med Microbiol. 2017;2017:6362804. doi: 10.1155/2017/6362804. Epub 2017 Feb 20.

9.
10.

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.

Mitchell D, Guertin JR, Iliza AC, Fanton-Aita F, LeLorier J.

Mol Diagn Ther. 2017 Feb;21(1):95-105. doi: 10.1007/s40291-016-0238-8.

11.

A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.

Iliza AC, Matteau A, Guertin JR, Mitchell D, Fanton-Aita F, Dubois A, Dubé MP, Tardif JC, LeLorier J.

Pharmacogenomics. 2016 Oct;17(15):1693-1706. Epub 2016 Oct 10.

PMID:
27719379
12.

Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population.

Fanton-Aita F, Matteau A, Iliza AC, Mitchell D, Guertin JR, Dubois A, Dubé MP, Tardif JC, LeLorier J.

Curr Med Res Opin. 2016 Dec;32(12):1955-1958. Epub 2016 Sep 20.

PMID:
27648984
13.

Performance of the high-dimensional propensity score in adjusting for unmeasured confounders.

Guertin JR, Rahme E, LeLorier J.

Eur J Clin Pharmacol. 2016 Dec;72(12):1497-1505. Epub 2016 Aug 30.

14.

Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.

Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, Durand M, Hu N, Juurlink DN, Paterson JM, Targownik LE, Turin TC, Ernst P; and the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators, Suissa S, Dormuth CR, Hemmelgarn BR, Teare GF, Caetano P, Chateau D, Henry DA, Paterson JM, LeLorier J, Levy AR, Ernst P, Platt RW, Sketris IS.

JAMA Intern Med. 2016 Oct 1;176(10):1464-1473. doi: 10.1001/jamainternmed.2016.1522.

PMID:
27479930
15.

The missing cause approach to unmeasured confounding in pharmacoepidemiology.

Abrahamowicz M, Bjerre LM, Beauchamp ME, LeLorier J, Burne R.

Stat Med. 2016 Mar 30;35(7):1001-16. doi: 10.1002/sim.6818. Epub 2016 Jan 14.

PMID:
26932124
16.

Head to head comparison of the propensity score and the high-dimensional propensity score matching methods.

Guertin JR, Rahme E, Dormuth CR, LeLorier J.

BMC Med Res Methodol. 2016 Feb 19;16:22. doi: 10.1186/s12874-016-0119-1.

17.

Burden of illness of bone metastases in prostate cancer patients in Québec, Canada: A population-based analysis.

Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):307-14. doi: 10.5489/cuaj.2707.

18.

Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug.

Guertin JR, Mitchell D, Ali F, LeLorier J.

Clinicoecon Outcomes Res. 2015 Oct 6;7:497-503. doi: 10.2147/CEOR.S90386. eCollection 2015.

19.

Diagnostic accuracy of algorithms to identify hepatitis C status, AIDS status, alcohol consumption and illicit drug use among patients living with HIV in an administrative healthcare database.

Durand M, Wang Y, Venne F, Lelorier J, Tremblay CL, Abrahamowicz M.

Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):943-50. doi: 10.1002/pds.3808. Epub 2015 Jun 24.

PMID:
26114918
20.

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P.

Mult Scler Relat Disord. 2015 May;4(3):202-18. doi: 10.1016/j.msard.2015.02.005. Epub 2015 Mar 2. Review.

21.

Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada.

Ouellet E, Durand M, Guertin JR, LeLorier J, Tremblay CL.

Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):23-9.

22.

Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.

Guertin J, LeLorier J, Durand M, Gow R, Holbrook A, Levine M.

J Popul Ther Clin Pharmacol. 2014;21(3):e357-69. Epub 2014 Oct 8.

PMID:
25326915
23.

Penicillin to prevent recurrent leg cellulitis.

Durand M, Wistaff R, Lelorier J.

N Engl J Med. 2013 Aug 29;369(9):880. doi: 10.1056/NEJMc1307321. No abstract available.

PMID:
23984745
24.

Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.

Poulin F, Khairy P, Roy D, Levesque S, Talajic M, Guertin JR, Lelorier J; Atrial Fibrillation and Congestive Heart Failure Trial Investigators.

Can J Cardiol. 2013 Oct;29(10):1256-62. doi: 10.1016/j.cjca.2013.03.005. Epub 2013 Jun 7.

PMID:
23751149
25.

Future MS care: a consensus statement of the MS in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Coles A, Elovaara I, Havrdová E, Hommes O, Lelorier J, Morrow SA, Oreja-Guevara C, Rijke N, Schippling S.

J Neurol. 2013 Feb;260(2):462-9. doi: 10.1007/s00415-012-6656-6. Epub 2012 Aug 31.

26.

What determines propensity score depends on what we are determining propensity for: comment on a recent analysis of arterial access route in acute myocardial infarction.

Potter BJ, Mansour S, Lelorier J.

JACC Cardiovasc Interv. 2012 Jun;5(6):692; author reply 692-3. doi: 10.1016/j.jcin.2012.02.015. No abstract available.

27.

Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review.

Nkeng L, Cloutier AM, Craig C, Lelorier J, Moride Y.

Drug Saf. 2012 Jul 1;35(7):535-46. doi: 10.2165/11599720-000000000-00000. Review.

PMID:
22702638
28.

Risk of spontaneous intracranial hemorrhage in HIV-infected individuals: a population-based cohort study.

Durand M, Sheehy O, Baril JG, LeLorier J, Tremblay CL.

J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e34-41. doi: 10.1016/j.jstrokecerebrovasdis.2012.03.014. Epub 2012 May 2.

PMID:
22554568
29.

CNODES: the Canadian Network for Observational Drug Effect Studies.

Suissa S, Henry D, Caetano P, Dormuth CR, Ernst P, Hemmelgarn B, Lelorier J, Levy A, Martens PJ, Paterson JM, Platt RW, Sketris I, Teare G; Canadian Network for Observational Drug Effect Studies (CNODES).

Open Med. 2012 Oct 30;6(4):e134-40. Print 2012.

30.

Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea.

Kamdeu Fansi AA, Guertin JR, LeLorier J.

J Med Econ. 2012;15(1):53-60. doi: 10.3111/13696998.2011.629015. Epub 2011 Oct 24. Erratum in: J Med Econ. 2012;15(1):205.

PMID:
22023067
31.

Atrial fibrillation: a real-life observational study in the Québec population.

Guertin JR, Dorais M, Khairy P, Sauriol L, Matteau A, Poulin F, Talajic M, Roy D, LeLorier J.

Can J Cardiol. 2011 Nov-Dec;27(6):794-9. doi: 10.1016/j.cjca.2011.03.009. Epub 2011 Jul 13.

PMID:
21745721
32.

Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.

Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL.

J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):245-53. doi: 10.1097/QAI.0b013e31821d33a5.

PMID:
21499115
33.

Analysis of willingness to pay for implantable cardioverter-defibrillator therapy.

Nowakowska D, Guertin JR, Liu A, Abrahamowicz M, Lelorier J, Lespérance F, Brophy JM, Rinfret S.

Am J Cardiol. 2011 Feb 1;107(3):423-7. doi: 10.1016/j.amjcard.2010.09.041.

PMID:
21257009
34.

Willingness to pay to eliminate the risk of restenosis following percutaneous coronary intervention: a contingent valuation.

Guertin JR, Liu A, Abrahamowicz M, Cohen DJ, Ismail S, LeLorier J, Brophy JM, Rinfret S.

Circ Cardiovasc Qual Outcomes. 2011 Jan 1;4(1):46-52. doi: 10.1161/CIRCOUTCOMES.109.915421. Epub 2010 Dec 14.

PMID:
21156881
35.

Fracture risk of patients suffering from dizziness: a retrospective cohort study.

Kruschinski C, Sheehy O, Hummers-Pradier E, Lelorier J.

Eur J Gen Pract. 2010 Dec;16(4):229-35. doi: 10.3109/13814788.2010.517630. Epub 2010 Sep 19.

PMID:
20849315
36.

Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database.

Dorais M, Chirovsky D, Ambegaonkar B, Sazonov V, Davies G, Grant S, Lelorier J.

Can J Cardiol. 2010 Aug-Sep;26(7):e229-35.

37.
38.

The impact of a multidisciplinary information technology-supported program on blood pressure control in primary care.

Rinfret S, Lussier MT, Peirce A, Duhamel F, Cossette S, Lalonde L, Tremblay C, Guertin MC, LeLorier J, Turgeon J, Hamet P; LOYAL Study Investigators.

Circ Cardiovasc Qual Outcomes. 2009 May;2(3):170-7. doi: 10.1161/CIRCOUTCOMES.108.823765. Epub 2009 May 5.

PMID:
20031834
39.

Vascular access-related bloodstream infections in First Nations, community and teaching Canadian dialysis units, and other centre-level predictors.

Lafrance JP, Iqbal S, Lelorier J, Dasgupta K, Ritchie J, Ward L, Benaroya S, Barré P, Cantarovich M, Ghannoum M, Proulx N, Vasilevsky M, Rahme E.

Nephron Clin Pract. 2010;114(3):c204-12. doi: 10.1159/000262303. Epub 2009 Nov 28.

PMID:
19955826
40.

Effectiveness of a change in reperfusion strategy to primary percutaneous coronary intervention in a nonselected population.

Matteau A, Dorais M, Rinfret S, LeLorier J, Reeves F.

Can J Cardiol. 2009 Aug;25(8):e279-83.

41.

The risks and costs of multiple-generic substitution of topiramate.

Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.

Neurology. 2009 Jun 16;72(24):2122-9. doi: 10.1212/WNL.0b013e3181aa5300.

PMID:
19528520
42.

Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.

Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, MacLeod S.

Can J Clin Pharmacol. 2009 Summer;16(2):e273-81; discussion e282-4. Epub 2009 May 13.

PMID:
19439771
43.

Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures.

Sheehy O, Kindundu C, Barbeau M, LeLorier J.

Osteoporos Int. 2009 Sep;20(9):1583-94. doi: 10.1007/s00198-008-0829-2. Epub 2009 Jan 20.

PMID:
19153677
44.

A retrospective study of cholinesterase inhibitors for Alzheimer's disease: cerebrovascular disease as a predictor of patient outcomes.

Charbonneau C, Massoud F, Dorais M, LeLorier J.

Curr Med Res Opin. 2008 Dec;24(12):3287-94. doi: 10.1185/03007990802417713 .

PMID:
19032117
45.

Differences in persistence among different weekly oral bisphosphonate medications.

Sheehy O, Kindundu CM, Barbeau M, LeLorier J.

Osteoporos Int. 2009 Aug;20(8):1369-76. doi: 10.1007/s00198-008-0795-8. Epub 2008 Nov 20.

PMID:
19020921
46.

Drug utilization review of cholinesterase inhibitors in Quebec.

Massoud F, Dorais M, Charbonneau C, Lescrauwaet B, Boucher JM, LeLorier J.

Can J Neurol Sci. 2008 Sep;35(4):508-9. No abstract available. Erratum in: Can J Neurol Sci. 2009 Jan;36(1):132.

PMID:
18973072
47.

Vascular access-related infections: definitions, incidence rates, and risk factors.

Lafrance JP, Rahme E, Lelorier J, Iqbal S.

Am J Kidney Dis. 2008 Nov;52(5):982-93. doi: 10.1053/j.ajkd.2008.06.014. Epub 2008 Aug 29. Review.

PMID:
18760516
48.

Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study.

Tamim H, Duranceau A, Chen LQ, Lelorier J.

Drug Saf. 2008;31(8):675-84.

PMID:
18636786
49.

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.

LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.

Neurology. 2008 May 27;70(22 Pt 2):2179-86. doi: 10.1212/01.wnl.0000313154.55518.25.

PMID:
18505997
50.

Drug reimbursement policies in Canada--need for improved access to critical therapies.

LeLorier J, Bell A, Bougher DJ, Cox JL, Turpie AG.

Ann Pharmacother. 2008 Jun;42(6):869-73. doi: 10.1345/aph.1K373. Epub 2008 May 13.

PMID:
18477735

Supplemental Content

Loading ...
Support Center